Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.66 |
| ▸ | FGFR3 | P22607 | 10/20 | 0.66 |
| ▸ | FLT3 | P36888 | 6/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL3585405 | 0.94 | KDR (0.65) | KDRFGFR3FLT3 | |
| SCHEMBL13407717 | 0.92 | FLT3 (0.75) | KDRFGFR3FLT3 | |
| SCHEMBL3592576 | 0.86 | KDR (0.63) | KDRFGFR3FLT3 | |
| Formic Acid SCHEMBL3596436 | 0.86 | KDR (0.68) | KDRFGFR3FLT3 | |
| SCHEMBL20903378 | 0.84 | KDR (0.71) | KDRFGFR3FLT3 | |
| SCHEMBL13407731 | 0.83 | KDR (0.62) | KDRFGFR3FLT3 | |
| Hydrochloric Acid SCHEMBL17157031 | 0.83 | KDR (0.61) | KDRFGFR3FLT3 | |
| SCHEMBL13336414 | 0.81 | KDR (0.67) | KDRFGFR3FLT3 | |
| SCHEMBL15195596 | 0.81 | KDR (0.64) | KDRFGFR3FLT3 | |
| SCHEMBL17166898 | 0.81 | KDR (0.63) | KDRFGFR3FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121687-B1 | TRICYCLIC AMINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2015-10-14 | — | — | EP | claimed |
| EP-2121687-B1 | TRICYCLIC AMINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2015-10-14 | — | — | EP | disclosed |
| EP-2121687-B1 | TRICYCLIC AMINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2015-10-14 | — | — | EP | disclosed |
| US-8513276-B2 | Imidazo[1,2-a]pyridine compounds for use in treating cancer | ASTEX THERAPEUTICS LIMITED (GB) | 2013-08-20 | — | — | US | disclosed |
| US-8513276-B2 | Imidazo[1,2-a]pyridine compounds for use in treating cancer | ASTEX THERAPEUTICS LIMITED (GB) | 2013-08-20 | — | — | US | disclosed |
| US-8513276-B2 | Imidazo[1,2-a]pyridine compounds for use in treating cancer | ASTEX THERAPEUTICS LIMITED (GB) | 2013-08-20 | — | — | US | disclosed |
| US-20100093718-A1 | Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093718-A1 | Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093718-A1 | Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| EP-2121687-A2 | TRICYCLIC AMINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | Astex Therapeutics Limited (GB) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008078100-A2 | TRICYCLIC AMINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008078100-A2 | TRICYCLIC AMINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093718-A1 | Compounds | FGFR1, FGFR2, PDGFRB | KDR 7/4885FGFR3 6/4885FLT3 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.